FDA finalizes its guidance on how psychedelic drug trials should run

What did the FDA publish?

A final version of "Psychedelic Drugs: Considerations for Clinical Investigations," announced in the Federal Register on July 14, 2026. It replaces the draft of the same title issued on June 26, 2023; the FDA says it considered the comments on the draft and made "a few revisions" for clarity.¹

The guidance is advice to drug developers, not a regulation. The notice says it "does not establish any rights for any person and is not binding on FDA or the public."¹ It covers classic psychedelics such as psilocybin and LSD and entactogens such as MDMA, and it was prepared by the Division of Psychiatry at the FDA's drug center.²

What does it ask trial sponsors to do?

The main recommendations in the final text:²

• Two monitors for the whole session. The lead monitor should be a licensed health care provider with graduate-level training and clinical experience in psychotherapy. The assistant should have a nursing or bachelor's degree and at least 1 year of clinical experience in a licensed mental health setting. If the lead isn't a physician, a licensed on-call physician should be able to reach the site within 15 minutes.
• Care with placebos. Participants and staff can often tell who got the active drug, which the FDA calls functional unblinding. A traditional placebo "can be problematic" for measuring efficacy, so sponsors may consider alternatives such as a lower amount of the psychedelic or another psychoactive drug.
• Longer follow-up. For chronic conditions such as PTSD or major depression, sponsors should test the effect at 12 weeks in a double-blind design before a first application, and keep following people after that. The FDA calls blinded follow-up of typically 12 months the most informative design.
• The therapy question. As of publication, the contribution of psychotherapy to any benefit "has not been characterized," and sponsors should describe and justify the support model they use.
• Safety and consent. Consent forms should explain that perception, thinking and judgment can change for many hours. Sponsors should consider a formal driving study and whether a risk management program (a REMS) will be needed after approval.
• Who enrolls. People with past psychedelic use can take part but shouldn't be overrepresented, because they're more likely to recognize the drug's effects.

Also on July 14, HHS's Health Resources and Services Administration asked for public input on training and care-delivery models for any future FDA-approved psychedelic, including in health centers and rural health clinics. Comments were due Aug. 13, 2026.³

Does it change psilocybin's legal status?

No. The guidance applies to investigational products in clinical trials, and it says research with Schedule I psychedelics must follow DEA rules on handling and storage.² A footnote explains that once the FDA approves a drug, it would be placed in Schedule II, III, IV or V according to its abuse potential.² That step hasn't happened for any psilocybin product. Psilocybin and psilocyn remain in Schedule I on the DEA's list dated Oct. 21, 2026,⁴ and on Nevada's own Schedule I list, NAC 453.510.⁵

What does it mean for someone in Nevada?

Nevada has no legal psilocybin program, so clinical trials are where Nevadans can receive psilocybin treatment under federal research rules, and this guidance is the FDA's template for those studies. ClinicalTrials.gov lists one active trial with a Las Vegas site that tests psilocybin itself: Compass Pathways' study of COMP360 for PTSD, which was recruiting at its Las Vegas site when we checked on Nov. 2.⁶ Our guide to psilocybin therapy in Las Vegas lists the Nevada trials and the nearest ones in other states.

Any psilocybin application to the FDA will rest on studies of this kind. Compass says it expects to finish submitting its application for treatment-resistant depression in the fourth quarter of 2026;⁸ our post on the Compass timeline explains what would have to follow, at the DEA and in Nevada, before any prescription use. Until then, psilocybin outside a trial remains illegal here; the Nevada law page has the details.